NUAK2 and RCan2 participate in the p53 mutant pro-tumorigenic network

Cite This

Files in this item

Checksum: MD5:aab72641dfc44c451826eef2492ed56c

MAMMARELLA, Eleonora, Carlotta ZAMPIERI, Emanuele PANATTA, Gerry MELINO, Ivano AMELIO, 2021. NUAK2 and RCan2 participate in the p53 mutant pro-tumorigenic network. In: Biology Direct. BioMed Central. 16, 11. eISSN 1745-6150. Available under: doi: 10.1186/s13062-021-00296-5

@article{Mammarella2021NUAK2-56524, title={NUAK2 and RCan2 participate in the p53 mutant pro-tumorigenic network}, year={2021}, doi={10.1186/s13062-021-00296-5}, volume={16}, journal={Biology Direct}, author={Mammarella, Eleonora and Zampieri, Carlotta and Panatta, Emanuele and Melino, Gerry and Amelio, Ivano}, note={Article Number: 11} }

<rdf:RDF xmlns:dcterms="" xmlns:dc="" xmlns:rdf="" xmlns:bibo="" xmlns:dspace="" xmlns:foaf="" xmlns:void="" xmlns:xsd="" > <rdf:Description rdf:about=""> <dc:creator>Melino, Gerry</dc:creator> <dc:date rdf:datatype="">2022-02-11T07:56:09Z</dc:date> <dcterms:title>NUAK2 and RCan2 participate in the p53 mutant pro-tumorigenic network</dcterms:title> <dc:contributor>Melino, Gerry</dc:contributor> <dcterms:hasPart rdf:resource=""/> <dcterms:issued>2021</dcterms:issued> <dc:creator>Panatta, Emanuele</dc:creator> <dcterms:available rdf:datatype="">2022-02-11T07:56:09Z</dcterms:available> <dc:creator>Amelio, Ivano</dc:creator> <dspace:isPartOfCollection rdf:resource=""/> <foaf:homepage rdf:resource="http://localhost:8080/jspui"/> <dc:creator>Zampieri, Carlotta</dc:creator> <dspace:hasBitstream rdf:resource=""/> <dc:contributor>Panatta, Emanuele</dc:contributor> <dc:contributor>Mammarella, Eleonora</dc:contributor> <dc:language>eng</dc:language> <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/> <dcterms:isPartOf rdf:resource=""/> <dc:contributor>Amelio, Ivano</dc:contributor> <bibo:uri rdf:resource=""/> <dc:contributor>Zampieri, Carlotta</dc:contributor> <dcterms:abstract xml:lang="eng">Most inactivating mutations in TP53 gene generates neomorphic forms of p53 proteins that experimental evidence and clinical observations suggest to exert gain-of-function effects. While massive effort has been deployed in the dissection of wild type p53 transcriptional programme, p53 mutant pro-tumorigenic gene network is still largely elusive. To help dissecting the molecular basis of p53 mutant GOF, we performed an analysis of a fully annotated genomic and transcriptomic human pancreatic adenocarcinoma to select candidate players of p53 mutant network on the basis their differential expression between p53 mutant and p53 wild-type cohorts and their prognostic value. We identified NUAK2 and RCan2 whose p53 mutant GOF-dependent regulation was further validated in pancreatic cancer cellular model. Our data demonstrated that p53R270H can physically bind RCan2 gene locus in regulatory regions corresponding to the chromatin permissive areas where known binding partners of p53 mutant, such as p63 and Srebp, bind. Overall, starting from clinically relevant data and progressing into experimental validation, our work suggests NUAK2 and RCan2 as novel candidate players of the p53 mutant pro-tumorigenic network whose prognostic and therapeutic interest might attract future studies.</dcterms:abstract> <dc:creator>Mammarella, Eleonora</dc:creator> <dc:rights>Attribution 4.0 International</dc:rights> <dcterms:rights rdf:resource=""/> </rdf:Description> </rdf:RDF>

Downloads since Feb 11, 2022 (Information about access statistics)

Mammarella_2-81pdn195e1zt2.pdf 61

This item appears in the following Collection(s)

Attribution 4.0 International Except where otherwise noted, this item's license is described as Attribution 4.0 International

Search KOPS


My Account